Catalyst Wire Dossier Catalyst Wire Dossier

chemotherapy regimens typical in neoadjuvant settings

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for chemotherapy regimens typical in neoadjuvant settings, covering 2023-03-06 to 2023-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling [Phase 2]

See pricing